Temporary suspension of Abivax shares on Euronext Paris

Biotechnology company Abivax has announced the temporary suspension of trading of its ordinary shares on Euronext Paris. Scheduled for July 1, 2026, the suspension was implemented at the company's request at the market opening at 9:00 a.m. (CEST). This decision is part of a public offering of its American Depositary Shares (ADS) in the United States. This temporary halt is intended to allow for the confirmation of allocations to investors and the announcement of the final terms of the offering.

The company intends to resume trading on Euronext Paris later that day, around 3:30 p.m. (CEST). Abivax is in clinical development and focuses on treatments for chronic inflammatory diseases. The operation was designed to stabilize the immune response in patients through the body's natural regulatory mechanisms.